DBV Technologies S.A. (NASDAQ:DBVT) Short Interest Down 5.3% in November

DBV Technologies S.A. (NASDAQ:DBVT) was the target of a large decrease in short interest in November. As of November 15th, there was short interest totalling 1,260,000 shares, a decrease of 5.3% from the October 31st total of 1,330,000 shares. Based on an average trading volume of 671,600 shares, the days-to-cover ratio is currently 1.9 days. Currently, 1.3% of the company’s shares are short sold.

DBV Technologies Price Performance

Shares of NASDAQ DBVT opened at $3.89 on Tuesday. The firm has a 50-day simple moving average of $3.43 and a two-hundred day simple moving average of $4.15. DBV Technologies has a 1 year low of $2.20 and a 1 year high of $10.70.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on DBVT shares. JMP Securities reiterated a “market outperform” rating and issued a $25.00 price target on shares of DBV Technologies in a research report on Tuesday, September 24th. StockNews.com initiated coverage on shares of DBV Technologies in a report on Saturday. They set a “hold” rating on the stock. Finally, HC Wainwright raised their price objective on DBV Technologies from $25.00 to $35.00 and gave the company a “buy” rating in a research note on Thursday, October 24th.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.